Cryoglobulinaemic neuropathy manifesting with restless legs syndrome

Gemignani, F; Marbini, A; Giovanni, G. Di; Salih, Sultan; Margarito, Francesco P.; Pavesi, Giovanni; Terzano, Mario Giovanni

doi:10.1016/s0022-510x(97)00187-1

Cited by 56 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Generally, the onset is subacute and PNS symptoms are the initial manifestation of cryoglobulinemic vasculitis in half of the patients. Rapidly invalidating acute pictures requiring aggressive treatment may also occur [59][60][61]. Electrophysiological studies display axonopathy in all cases, which is consistent with the histopathological findings of axonal degeneration [61].…”

Section: Cryoglobulinemiasupporting

confidence: 63%

The clinical spectrum of the neurological involvement in vasculitides

Rossi

Comite

2009

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Cryoglobulinemiasupporting

confidence: 63%

The clinical spectrum of the neurological involvement in vasculitides

Rossi

Comite

2009

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Secondary RLS is associated with cryoglobulinemia and neuropathies of toxic, diabetic or vasculitic origin, which all are characterised by predominant axonal loss 12 35 36. It may be intriguing to regard CMT2 as a model for RLS pathogenesis, but both clinical and neurophysiological evidence suggests that CMT1 as a primary disorder of myelination and myelin maintenance is associated with progressive axonal damage, too.…”

Section: Discussionmentioning

confidence: 99%

Sleep disorders in Charcot-Marie-Tooth disease type 1

Boentert

Knop

Schuhmacher

et al. 2013

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

show abstract

“…[86][87][88][89][90][91][92][93] These studies revealed that the axonal-sensory and the small-fi ber polyneuropathies are the most common causes of RLS. [89][90][91][92][93] An imbalanced equilibrium in the dorsal horn of the spinal grey matter among the excitatory nociceptive inputs, due to the peripheral neuropathy, and the inhibitory ones descending from the diencephalon might explain the occurrence of RLS in the course of peripheral neuropathy. 33 Differently from primary RLS, patients affected by RLS due to polyneuropathy identify the sensory discomfort in the legs as painful sensations.…”

Section: Vesper's Cursementioning

confidence: 98%

Restless legs syndrome: differential diagnosis and management with rotigotine

Merlino

Serafini²,

Robiony³

et al. 2009

NDT

View full text Add to dashboard Cite

RLS is a common sleep disorder with distinctive clinical features. The prevalence of RLS in Caucasians and North Americans ranges from 5% to 10%. However, only some of these subjects (almost the 3% of the general population) report being affected by a frequent and severe form of the sleep disorder. RLS is diagnosed clinically by means of four internationally recognized criteria that summarize the main characteristics of the sleep disorder. Besides the essential criteria, supportive and associated features of RLS have been established by experts in order to help physicians treat patients with doubtful symptoms. Several clinical conditions may mimic this sleep disorder. In order to increase the sensibility and specifi city of RLS diagnosis, doctors should perform a meticulous patient history and then an accurate physical and neurological examination. Dopamine agonists are recognized as the preferred fi rst-line treatment for RLS. Rotigotine is a non-ergoline dopamine agonist with selectivity for D1, D2 and D3 receptors. The drug is administered via transdermal patches which release rotigotine for 24 hours. Four clinical trials demonstrated that this compound is able to improve RLS symptomatology with few and moderate adverse events. Head to head trials are required to compare the effi cacy and tolerability of rotigotine with other dopamine agonists administered via oral intake. Rotigotine has been approved by the FDA and EMEA for Parkinson's disease. For the treatment of moderate to severe idiopathic RLS, rotigotine has been recommended for approval by the EMEA and is under review by the FDA.

show abstract

Cryoglobulinaemic neuropathy manifesting with restless legs syndrome

Cited by 56 publications

References 27 publications

The clinical spectrum of the neurological involvement in vasculitides

The clinical spectrum of the neurological involvement in vasculitides

Sleep disorders in Charcot-Marie-Tooth disease type 1

Restless legs syndrome: differential diagnosis and management with rotigotine

Contact Info

Product

Resources

About